Today marks the close of the public comment window on the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. If finalized, the rule would constrain — though not eliminate — the supply of compounded GLP-1 medications routed through 503B FDA-registered outsourcing facilities. The 503A patient-specific pathway is explicitly unaffected by the proposal.
Industry trade groups, several state pharmacy associations, and a coalition of telehealth providers filed comments arguing for either a narrower scope or grandfathering of existing programs. Patient-advocacy groups submitted comments on both sides, with some arguing that 503B routing offers stronger quality controls and others arguing that supply constraints would push patients toward less-regulated overseas sources.
A final rule is not expected for several months. In the interim, providers that already disclose 503A pathways for patient-specific prescriptions should be largely unaffected; programs that rely on 503B batch supply may need to reroute over time. We will update our Pharmacy Traceability scoring criteria once the rule is finalized to reflect the practical landscape.